20 Million Stopped GLP-1s. What Happens Next? | Give It To Me Straight, Doc - Ep. 9

GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound have transformed weight loss. But what happens when patients want to stop taking them? Does the weight return, and are these medications meant to be lifelong? On this episode of Give It to Me Straight, Doc, host Anjalee Khemlani speaks with Sean Duffy, co-founder and CEO of Omada Health; Dr. Shantanu Gaur, co-founder and CEO of Allurion; and Jared Holz, health care sector strategist at Mizuho. They discuss why GLP-1s are not a silver bullet, the challenges of side effects and muscle loss, why some patients stop treatment, and the support needed to achieve lasting results. The conversation also explores non-surgical alternatives, the next generation of pills and longer-lasting injections, and research into possible uses involving addiction, inflammation and Alzheimer’s disease. This program is for informational purposes only and is not a substitute for professional medical advice. Presented by Tampa General Hospital and USF Health Morsani College of Medicine. Have questions about healthcare? Submit a question at the link below, and it could be featured on the next episode: https://www.tgh.org/give-it-to-me-str...